Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
0.2500
-0.0107 (-4.10%)
At close: Mar 17, 2026, 4:00 PM EDT
0.2574
+0.0074 (2.96%)
After-hours: Mar 17, 2026, 7:59 PM EDT
Plus Therapeutics Employees
Plus Therapeutics had 21 employees as of December 31, 2024. The number of employees increased by 1 or 5.00% compared to the previous year.
Employees
21
Change (1Y)
1
Growth (1Y)
5.00%
Revenue / Employee
$248,238
Profits / Employee
-$1,066,000
Market Cap
42.89M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 21 | 1 | 5.00% |
| Dec 31, 2023 | 20 | 3 | 17.65% |
| Dec 31, 2022 | 17 | 3 | 21.43% |
| Dec 31, 2021 | 14 | 2 | 16.67% |
| Dec 31, 2020 | 12 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| NextCure | 43 |
| Palatin Technologies | 29 |
| Lisata Therapeutics | 26 |
| MiNK Therapeutics | 23 |
| Atossa Therapeutics | 15 |
| Sensei Biotherapeutics | 15 |
| CervoMed | 15 |
| Apollomics | 13 |
PSTV News
- 5 days ago - Plus Therapeutics Reports 2025 Results, Business Progress and 2026 Anticipated Milestones for REYOBIQ™ Clinical Program and CNSide® Commercial Rollout - GlobeNewsWire
- 20 days ago - Plus Therapeutics Announces New Category III CPT Code for Convection-Enhanced Delivery Used with REYOBIQ™ - GlobeNewsWire
- 7 weeks ago - Plus Therapeutics, Inc. (PSTV) Discusses Business Update, REYOBIQ Clinical Program Progress, and Recent Financial Offering Transcript - Seeking Alpha
- 7 weeks ago - Plus Therapeutics to Provide Business Update and Host Conference Call on Thursday, January 22, 2026 at 9:00 A.M. ET - GlobeNewsWire
- 2 months ago - Penny Cancer Stock Plus Therapeutics Raises $15 Million At Discount, Stock Plunges - Benzinga
- 2 months ago - Plus Therapeutics Announces Pricing of Upsized $15 Million Public Offering - GlobeNewsWire
- 2 months ago - Plus Therapeutics Announces Read Out of Type B Meeting with the FDA with Goal of Accelerating Approval of REYOBIQ™ for Leptomeningeal Metastases - GlobeNewsWire
- 3 months ago - Plus Therapeutics Expands CNSide Assay Platform to State of California - GlobeNewsWire